CARTITUDE-2 Cohort B: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and Early Relapse After Initial Therapy

What is the purpose of this trial? 

CARTITUDE-2 is a phase 2, multicohort study evaluating the efficacy and safety of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma (MM). Cohort B enrolled patients who had early relapse after initial therapy. These patients have functionally high-risk disease, as early relapse following autologous stem cell transplantation (ASCT) is associated with poor prognosis, representing an unmet medical need. Updated results from CARTITUDE-2 cohort B to be presented. 

In this video:

Dr. Niels Van de Donk (Amsterdam University Medical Center, Amsterdam, Netherlands) discusses CARTITUDE-2 Cohort B updates evaluating CAR T therapy Cilta-Cel in multiple myeloma patients who had early relapse after initial therapy.

Conclusion:

This functionally high-risk patient population with early relapse after initial therapy experienced deep and durable responses with manageable safety following a single cilta-cel infusion. Cilta-cel led to responses in patients with ineffective or insufficient response to ASCT. Follow-up is ongoing and responses continue to deepen. We will present updated and detailed pharmacokinetics (PK), cytokine, and CAR-T subset analyses as well as clinical correlation to provide insight into biological correlates of efficacy and safety in these patients.

Clinical trial information: NCT04133636